TScan Therapeutics, Inc.
Prognozy (mln)
Okres |
2024-12-31 |
2025-12-31 |
2026-12-31 |
2027-12-31 |
2028-12-31 |
2029-12-31 |
Przychód (średnia) |
3.61 |
7.40 |
7.94 |
72.02 |
59.55 |
124.64 |
Przychód Δ r/r |
0.00% |
105.02% |
7.32% |
807.12% |
-17.31% |
109.31% |
Przychód (min) |
2.92 |
1.96 |
7.94 |
72.02 |
23.33 |
48.83 |
Przychód (max) |
4.69 |
13.49 |
7.94 |
72.02 |
104.87 |
219.51 |
EBITDA (średnia) |
-3.61 |
-7.40 |
-7.94 |
-72.02 |
-59.55 |
-124.64 |
EBIT (średnia) |
-3.61 |
-7.40 |
-7.94 |
-72.02 |
-59.55 |
-124.64 |
EBIT % |
-100.00% |
-100.00% |
-100.00% |
-100.00% |
-100.00% |
-100.00% |
Zysk netto (średni) |
-141.87 |
-141.59 |
-159.03 |
-99.89 |
-105.64 |
-66.82 |
Zysk netto % |
-3931.58% |
-1913.87% |
-2003.10% |
-138.70% |
-177.41% |
-53.61% |
EPS (średnia) |
-1.27 |
-1.26 |
-1.18 |
-0.85 |
-0.94 |
-0.60 |
Liczba analityków (Przychody) |
5 |
4 |
6 |
4 |
2 |
3 |
Liczba analityków (EPS) |
5 |
5 |
5 |
3 |
1 |
1 |
symbol |
TCRX |
TCRX |
TCRX |
TCRX |
TCRX |
TCRX |